Quince Therapeutics (QNCX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Quince Therapeutics is set to release its Q2 2025 earnings on August 12th, with analysts anticipating an earnings report of ($0.28) per share for the quarter.
• The company recently posted earnings of ($0.34) per share, falling short of analysts' expectations by $0.10.
• Several analysts have a positive outlook on Quince Therapeutics, with an average "Buy" rating and a consensus price target of $8.29 for the stock.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Quince Therapeutics to post earnings of ($0.28) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Stock Down 1.2%

QNCX traded down $0.02 during midday trading on Friday, reaching $1.65. 188,608 shares of the company were exchanged, compared to its average volume of 207,301. The company has a debt-to-equity ratio of 0.82, a quick ratio of 4.05 and a current ratio of 4.05. The company's fifty day moving average price is $1.55 and its 200 day moving average price is $1.36. The company has a market cap of $88.47 million, a price-to-earnings ratio of -1.19 and a beta of 1.02. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45.

Analysts Set New Price Targets

QNCX has been the subject of a number of recent research reports. D. Boral Capital reissued a "buy" rating and set a $4.00 price objective on shares of Quince Therapeutics in a report on Thursday, July 17th. Citigroup started coverage on Quince Therapeutics in a report on Tuesday. They issued an "outperform" rating for the company. Citizens Jmp assumed coverage on Quince Therapeutics in a report on Tuesday. They issued a "strong-buy" rating and a $9.00 target price for the company. Wall Street Zen lowered Quince Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, JMP Securities assumed coverage on Quince Therapeutics in a report on Tuesday. They set a "market outperform" rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat, Quince Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $8.29.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.